Perspective Therapeutics updates corporate presentation on 212Pb radiopharmaceutical pipeline

Perspective Therapeutics, Inc.

Neuroendocrine tumor trial VMT-α-NET Phase 1/2a shows sustained anti-tumor activity and good tolerability; no renal function decline observed.
Metastatic melanoma program VMT01/02 Phase 1/2a dosing ongoing; treatment-emergent AEs summarized in presentation.
PSV359 Phase 1/2a targets FAP-α expression on tumor and stroma.
Platform uses proprietary chelator optimized for lead-212 RPTs and on-demand regional manufacturing infrastructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.